Short Interest in IPSEN (OTCMKTS:IPSEY) Increases By 73.1%

IPSEN (OTCMKTS:IPSEY) was the recipient of a large increase in short interest during the month of May. As of May 15th, there was short interest totaling 514 shares, an increase of 73.1% from the April 30th total of 297 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average trading volume of 2,506 shares, the days-to-cover ratio is presently 0.2 days.

Analysts Set New Price Targets

IPSEY has been the topic of several recent research reports. Zacks Research raised shares of IPSEN to a “hold” rating in a research report on Friday. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold”.

IPSEN Trading Down 2.8%

IPSEY stock traded down $1.25 during mid-day trading on Tuesday, hitting $43.20. 261 shares of the company were exchanged, compared to its average volume of 2,336. The business has a fifty day simple moving average of $47.73 and a 200-day simple moving average of $42.52. IPSEN has a 12-month low of $28.66 and a 12-month high of $51.10.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).